Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT06702995 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castrate-Resistant Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG: XNW5004
DRUG: enzalutamide

Sponsor

Evopoint Biosciences Inc.